Debra S. Perlow

3.1k total citations · 1 hit paper
24 papers, 2.5k citations indexed

About

Debra S. Perlow is a scholar working on Molecular Biology, Organic Chemistry and Social Psychology. According to data from OpenAlex, Debra S. Perlow has authored 24 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Molecular Biology, 11 papers in Organic Chemistry and 5 papers in Social Psychology. Recurrent topics in Debra S. Perlow's work include Chemical Synthesis and Analysis (9 papers), Receptor Mechanisms and Signaling (6 papers) and Neuroendocrine regulation and behavior (5 papers). Debra S. Perlow is often cited by papers focused on Chemical Synthesis and Analysis (9 papers), Receptor Mechanisms and Signaling (6 papers) and Neuroendocrine regulation and behavior (5 papers). Debra S. Perlow collaborates with scholars based in United States and United Kingdom. Debra S. Perlow's co-authors include Joshua Boger, Emilio A. Emini, Roger Freidinger, Daniel F. Veber, Richard Saperstein, Jerry R. Brooks, Byron H. Arison, William C. Randall, Ralph Hirschmann and Ruth F. Nutt and has published in prestigious journals such as Nature, Science and Journal of Virology.

In The Last Decade

Debra S. Perlow

23 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide

1985 991 citations Emilio A. Emini, Debra S. Perlow et al. Journal of Virology profile →

Peers

Countries citing papers authored by Debra S. Perlow

Since Specialization

Citations

This map shows the geographic impact of Debra S. Perlow's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Debra S. Perlow with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Debra S. Perlow more than expected).

Fields of papers citing papers by Debra S. Perlow

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Debra S. Perlow. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Debra S. Perlow. The network helps show where Debra S. Perlow may publish in the future.

Co-authorship network of co-authors of Debra S. Perlow

This figure shows the co-authorship network connecting the top 25 collaborators of Debra S. Perlow. A scholar is included among the top collaborators of Debra S. Perlow based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Debra S. Perlow. Debra S. Perlow is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Practical Synthesis of 4‐Fluoro‐2‐(methylthio)benzylamine and the Corresponding Sulfone and Sulfonamide 2007 ·Synthetic Communications ·Debra S. Perlow, (unknown), (unknown), John Wai, Melissa S. Egbertson	5
2	Synthesis of Protected Lactam-Bridged Dipeptides 2003 ·Humana Press eBooks ·Debra S. Perlow, Roger Freidinger	0
3	Nonpeptide oxytocin antagonists: Analogs of L-371,257 with improved potency 1999 ·Bioorganic & Medicinal Chemistry Letters ·Peter D. Williams, Mark G. Bock, B. Evans, Roger Freidinger, Steven N. Gallicchio, (unknown), Marlene A. Jacobson, (unknown), (unknown), Edward V. Lis, Stuart R. Michelson, Joseph Pawluczyk, Debra S. Perlow, Douglas J. Pettibone, (unknown), Duane R. Reiss, Christopher Salvatore, Kenneth J. Stauffer, (unknown)	13
4	Nonpeptide oxytocin antagonists: Potent, orally bioavailable analogs of L-371,257 containing A 1-R-(pyridyl)ethyl ether terminus 1998 ·Bioorganic & Medicinal Chemistry Letters ·(unknown), Mark G. Bock, Roger Freidinger, (unknown), Edward V. Lis, Joseph Pawluczyk, Debra S. Perlow, Douglas J. Pettibone, (unknown), Duane R. Reiss, Peter D. Williams, (unknown)	9
5	Conformationally constrained o-tolylpiperazine camphorsulfonamide oxytocin antagonists. Structural modifications that provide high receptor affinity and suggest a bioactive conformation. 1994 ·Bioorganic & Medicinal Chemistry ·Peter D. Williams, Richard G. Ball, Bradley V. Clineschmidt, J. Chris Culberson, Jill M. Erb, Roger Freidinger, Joseph Pawluczyk, Debra S. Perlow, Douglas J. Pettibone, Daniel F. Veber	4
6	ChemInform Abstract: 1‐(((7,7‐Dimethyl‐2(S)‐(2(S)‐amino‐4‐(methylsulfonyl)butyramido) bicyclo(2.2.1)heptan‐1(S)‐yl)methyl)sulfonyl)‐4‐(2‐methylphenyl) piperazine (L‐368,899): An Orally Bioavailable, Non‐Peptide Oxytocin Antagonist with Potential Utility for Managing Preterm Labor. 1994 ·ChemInform ·Paul Williams, Paul Anderson, Richard G. Ball, Mark G. Bock, (unknown), Simon Chiu, Bradley V. Clineschmidt, J. Chris Culberson, Jill M. Erb, B. Evans, Stephanie L. Fitzpatrick, Roger Freidinger, Marc J. Kaufman, G. F. Lundell, (unknown), Joseph Pawluczyk, Debra S. Perlow, Douglas J. Pettibone, Steven M. Pitzenberger	13
7	Development of a novel class of cyclic hexapeptide oxytocin antagonists based on a natural product 1992 ·Journal of Medicinal Chemistry ·Peter Williams, Mark G. Bock, Roger D. Tung, Victor M. Garsky, Debra S. Perlow, Jill M. Erb, G. F. Lundell, (unknown), Willie L. Whitter	28
8	Use of N-Fmoc amino acid chlorides and activated 2-(fluorenylmethoxy)-5(4H)-oxazolones in solid-phase peptide synthesis. Efficient syntheses of highly N-alkylated cyclic hexapeptide oxytocin antagonists related to L-365,209 1992 ·The Journal of Organic Chemistry ·Debra S. Perlow, Jill M. Erb, (unknown), Roger D. Tung, Roger Freidinger, Peter D. Williams, Daniel F. Veber	31
9	Renin inhibitors containing conformationally restricted P1-P1' dipeptide mimetics 1991 ·Journal of Medicinal Chemistry ·Peter D. Williams, Debra S. Perlow, Linda S. Payne, M. K. HOLLOWAY, Peter K. S. Siegl, Terry W. Schorn, Robert J. Lynch, John Doyle, (unknown)	31
10	The selectivity of statine-based inhibitors against various human aspartic proteinases 1990 ·Biochemical Journal ·R A Jupp, Ben M. Dunn, J Jacobs, G P Vlasuk, Karen E. Arcuri, Daniel F. Veber, Debra S. Perlow, Linda S. Payne, Joshua Boger, (unknown), (unknown), J. ten Broeke, David Hangauer, (unknown), William J. Greenlee, John Kay	34
11	Design and discovery in the development of long-acting renin inhibitors 1990 ·Biochemical Society Transactions ·Daniel F. Veber, Linda S. Payne, Peter D. Williams, Debra S. Perlow, G. F. Lundell, (unknown), Peter K. S. Siegl, Charles S. Sweet, Roger Freidinger	3
12	Conformationally constrained tachykinin analogs which are selective ligands for the eledoisin binding site. 1986 ·Molecular Pharmacology ·(unknown), Gary G. Chicchi, Roger Freidinger, C. D. COLTON, Debra S. Perlow, (unknown), Neil R. Curtis, A.T. McKnight, Janet J. Maguire, Daniel F. Veber	33
13	ChemInform Abstract: Renin Inhibitors. Syntheses of Subnanomolar, Competitive, Transition‐State Analogue Inhibitors Containing a Novel Analogue of Statine. 1986 ·Chemischer Informationsdienst ·Joshua Boger, Linda S. Payne, Debra S. Perlow, (unknown), Martin Poe, Edward H. Blaine, E H Ulm, Terry W. Schorn, (unknown), Tai-Yuan Lin, Masao Kawai, D. H. RICH, Daniel F. Veber	8
14	Renin inhibitors. Syntheses of subnanomolar, competitive, transition-state analog inhibitors containing a novel analog of statine 1985 ·Journal of Medicinal Chemistry ·Joshua Boger, Linda S. Payne, Debra S. Perlow, (unknown), Martin Poe, Edward H. Blaine, E H Ulm, Terry W. Schorn, Bruce I. LaMont	111
15	ChemInform Abstract: ANGIOTENSIN‐CONVERTING ENZYME INHIBITORS: SYNTHESIS AND BIOLOGICAL ACTIVITY OF ACYLTRIPEPTIDE ANALOGS OF ENALAPRIL 1985 ·Chemischer Informationsdienst ·William J. Greenlee, (unknown), Debra S. Perlow, Arthur A. Patchett, E H Ulm, (unknown)	3
16	Angiotensin-converting enzyme inhibitors: synthesis and biological activity of acyltripeptide analogs of enalapril 1985 ·Journal of Medicinal Chemistry ·William J. Greenlee, (unknown), Debra S. Perlow, Arthur A. Patchett, E H Ulm, (unknown)	28
17	Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide breakdown → 1985 ·Journal of Virology ·Emilio A. Emini, (unknown), Debra S. Perlow, Joshua Boger	991
18	Conformational modifications of cyclic hexapeptide somatostatin analogs 1984 ·International journal of peptide & protein research ·Roger Freidinger, Debra S. Perlow, William C. Randall, Richard Saperstein, Byron H. Arison, Daniel F. Veber	47
19	Protected lactam-bridged dipeptides for use as conformational constraints in peptides 1982 ·The Journal of Organic Chemistry ·Roger Freidinger, Debra S. Perlow, Daniel F. Veber	186
20	A potent cyclic hexapeptide analogue of somatostatin 1981 ·Nature ·Daniel F. Veber, Roger Freidinger, Debra S. Perlow, William J. Paleveda, Frederick W. Holly, R. G. Strachan, Ruth F. Nutt, Byron H. Arison, Carl F. Homnick, William C. Randall, M. S. Glitzer, Richard Saperstein, Ralph Hirschmann	342

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact